Edward E. Koval

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

Zebiai Therapeutics, Inc. develops artificial intelligence to predict and optimize novel small molecule modulators for challenging drug targets. The company was founded by Richard Wagner and is headquartered in Chestnut Hill, MA.

X-Chem, Inc. operates as a biotechnology company. Its uses its DEX DNA encoded libraries and platform to discover small molecule leads against high-value therapeutic targets. The company was founded by Richard W. Wagner, Brant C. Binder, Matthew A. Clark, and Gordon M. Binder in 2009 and is headquartered in Waltham, MA.